List of Excipients in Branded Drug IMPOYZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Primus Pharmaceuticals Inc	IMPOYZ	clobetasol propionate	68040-713	BUTYLATED HYDROXYTOLUENE
Primus Pharmaceuticals Inc	IMPOYZ	clobetasol propionate	68040-713	CETOSTEARYL ALCOHOL
Primus Pharmaceuticals Inc	IMPOYZ	clobetasol propionate	68040-713	CYCLOMETHICONE
Primus Pharmaceuticals Inc	IMPOYZ	clobetasol propionate	68040-713	DIETHYLENE GLYCOL MONOETHYL ETHER

IMPOYZ Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 2, 2026

IMPOYZ is a prescription clobetasol propionate 0.025% cream for plaque psoriasis in patients 12 years and older. Its commercial differentiation is based on a lower-strength clobetasol concentration and cream vehicle rather than a new active ingredient. The strongest opportunities are formulation-led: improved skin feel, lower residue, preservative reduction, pump delivery, adherence support, and development of adjacent dosage forms.

IMPOYZ has limited protection from traditional active-ingredient patents because clobetasol propionate is an established generic corticosteroid. Its commercial position depends on formulation know-how, regulatory exclusivity, Orange Book listings, trademarks, clinical positioning, distribution, and the ability to demonstrate meaningful patient or prescriber value.

What is IMPOYZ and how does its formulation work?

IMPOYZ contains clobetasol propionate 0.025% in a topical cream vehicle. Clobetasol propionate is a highly potent corticosteroid used to reduce inflammatory and pruritic symptoms associated with plaque psoriasis.

The FDA-approved label limits treatment to short-term use. IMPOYZ is indicated for plaque psoriasis in patients aged 12 years and older, with treatment generally limited to two consecutive weeks and a maximum dosage of 50 grams per week. It is not intended for facial, axillary, or groin use, or for application to areas of skin atrophy unless directed by a physician (FDA, 2016).

IMPOYZ product profile

Attribute	IMPOYZ
Active ingredient	Clobetasol propionate
Strength	0.025%
Dosage form	Topical cream
Therapeutic class	Very-high-potency topical corticosteroid
Approved indication	Plaque psoriasis
Patient population	Adults and patients 12 years and older
Maximum labeled treatment	Two weeks
Maximum weekly quantity	50 grams
Regulatory pathway	FDA 505(b)(2) new drug application
NDA	208254
Biosimilar exposure	None; IMPOYZ is a small-molecule drug
Primary competitive risk	Generic clobetasol products and alternative topical vehicles

IMPOYZ uses a conventional oil-in-water cream architecture. Public labeling identifies excipients including carbomer, cetostearyl alcohol, cetyl alcohol, dimethicone, glyceryl stearate, medium-chain triglycerides, methylparaben, propylene glycol, purified water, sodium citrate dihydrate, stearyl alcohol, and tromethamine. The exact excipient system is commercially relevant because the vehicle affects spreadability, hydration, skin feel, drug release, irritation, and patient adherence (DailyMed, n.d.).

What excipients are used in IMPOYZ?

IMPOYZ uses excipients with distinct formulation functions rather than a single inert base.

Excipient or excipient class	Likely formulation role
Purified water	Continuous aqueous phase
Medium-chain triglycerides	Emollient oil phase and solvent support
Glyceryl stearate	Emulsifier and consistency agent
Cetostearyl alcohol	Emulsion stabilization and viscosity
Cetyl alcohol	Emolliency and texture
Stearyl alcohol	Body, viscosity, and phase stability
Dimethicone	Skin conditioning, occlusivity, and slip
Propylene glycol	Humectant and solvent
Carbomer	Rheology control and suspension stability
Tromethamine	Carbomer neutralization and pH adjustment
Sodium citrate dihydrate	Buffering and pH control
Methylparaben	Preservative
Purified water	Vehicle component

The excipient profile indicates a cream designed to balance pharmaceutical performance with conventional dermatology usability. Fatty alcohols and glyceryl stearate provide body and structural stability. Dimethicone supports spreadability and barrier feel. Propylene glycol can improve hydration and drug partitioning but may cause irritation in some patients. Methylparaben provides antimicrobial protection but creates a possible commercial differentiation point for preservative-free alternatives.

Which excipients create the greatest commercial value?

The highest-value excipient decisions are likely to involve:

1. Drug release control. Clobetasol propionate is highly lipophilic. The oil phase, emulsifier system, particle size, and solvent environment can materially influence release from the cream and uptake into the stratum corneum.

2. Skin tolerability. Propylene glycol and preservatives can create irritation or sensitization concerns in susceptible patients. A reformulated vehicle could target sensitive-skin populations.

3. Cosmetic acceptability. Greasiness, residue, whitening, tack, and washability affect adherence. These factors are important for psoriasis patients who may discontinue treatment when a topical product feels unpleasant.

4. Physical stability. Carbomer neutralization, pH, preservative effectiveness, emulsion droplet size, and active-ingredient distribution must remain within specification throughout shelf life.

5. Packaging compatibility. Clobetasol creams can interact with tube liners, pumps, elastomers, and dosing components. Packaging can alter delivered dose, rheology, and microbial protection.

What formulation opportunities exist for IMPOYZ?

The most attractive opportunities are follow-on formulations that preserve the 0.025% clobetasol strength while improving usability or expanding application sites.

Preservative-free IMPOYZ cream

A preservative-free cream could target patients with sensitive or compromised skin. The formulation would require a validated microbial-control strategy, potentially using:

• Single-dose or unit-dose packaging
• Airless pumps
• Reduced-container headspace
• Low-water-activity systems
• Sterile or microbiologically controlled manufacturing
• Alternative antimicrobial approaches compatible with topical use

The commercial benefit would depend on demonstrating lower irritation, longer persistence, or improved patient preference. A preservative-free claim alone may not justify a premium in a crowded generic market.

Low-residue or fast-absorbing cream

A lighter cream could address adherence barriers associated with greasy or occlusive products. Candidate changes include:

• Lower total fatty-alcohol content
• Alternative emollients
• Volatile or semi-volatile silicones where acceptable
• Smaller emulsion droplets
• Modified internal-phase volume
• Optimized rheology for rapid spreading

The main technical risk is maintaining clobetasol release and skin penetration while reducing occlusivity. A lighter vehicle could also reduce the residence time of the drug on the skin.

Pump-delivered IMPOYZ

A metered-dose pump could improve dose consistency and reduce contamination from repeated tube contact. It could also support clearer instructions based on pump actuations rather than fingertip units.

The key development requirements would include:

• Delivered-dose uniformity
• Priming and repriming studies
• Orientation testing
• Pump compatibility with the cream rheology
• Container-closure integrity
• Stability after repeated use
• Human factors validation

Pump packaging is most commercially credible when paired with a concrete benefit, such as easier dosing, reduced waste, or improved hygiene.

Foam, gel, lotion, or spray formulations

Alternative dosage forms could address scalp, hair-bearing, or larger body-surface applications. Potential formats include:

• Foam for scalp and hair-bearing psoriasis
• Gel for less occlusive application
• Lotion for broad body-surface coverage
• Spray for hard-to-reach areas
• Emulsion spray for rapid application

These products would not be simple excipient substitutions. They would involve new performance, packaging, and potentially clinical requirements. A foam or spray could expand the commercial market, but it would also increase manufacturing complexity and regulatory cost.

Barrier-supportive vehicle

A vehicle incorporating ceramides, fatty acids, cholesterol, colloidal oatmeal, or other barrier-supportive components could position the product around moisturization and steroid-sparing adherence. The formulation must avoid creating a new drug claim that requires additional clinical evidence.

A barrier-supportive excipient system is more commercially defensible if it produces measurable outcomes, such as reduced transepidermal water loss, improved patient-reported tolerability, or better adherence.

How does IMPOYZ compare with generic clobetasol products?

IMPOYZ competes with clobetasol propionate creams, ointments, gels, solutions, shampoos, and foams. Generic competition is especially strong because clobetasol propionate has long been available and is manufactured by multiple suppliers.

Competitive factor	IMPOYZ	Generic clobetasol products
Active ingredient	Clobetasol propionate	Clobetasol propionate
Strength	0.025%	Commonly 0.05%; some products use other strengths
Main vehicle	Cream	Cream, ointment, gel, solution, foam, shampoo
Brand differentiation	Formulation, brand, approved labeling	Price, availability, pharmacy substitution
FDA approval advantage	Original approved IMPOYZ NDA	ANDA-based products where applicable
Payer position	May face higher patient cost	Usually lower-cost alternatives
Prescriber rationale	Lower-strength formulation and vehicle attributes	Familiarity and price
Main weakness	Limited active-ingredient differentiation	Variable patient experience across vehicles

The 0.025% concentration gives IMPOYZ a potential positioning advantage over 0.05% clobetasol products for prescribers seeking a lower concentration within the clobetasol category. That distinction does not eliminate generic substitution risk. Pharmacies and payers may prioritize lower acquisition cost unless the product has formulary access or a documented clinical advantage.

When did IMPOYZ lose regulatory exclusivity?

IMPOYZ received FDA approval in 2016. A 505(b)(2) product containing a previously approved active ingredient can receive three years of exclusivity for certain new clinical investigations or changes in the product. That period would have expired in 2019, assuming the standard three-year period began on the approval date.

The regulatory exclusivity period does not necessarily correspond to patent expiration. Patent protection can continue after FDA exclusivity ends, but the commercial value depends on the scope, validity, enforceability, and Orange Book listing status of the relevant patents.

What patents protect IMPOYZ?

The active ingredient, clobetasol propionate, is old and does not provide meaningful new chemical entity protection for IMPOYZ. Any remaining patent value would more likely relate to:

• The specific 0.025% cream formulation
• Vehicle composition
• Particle size or active-ingredient distribution
• Topical treatment methods
• Dosing schedules
• Packaging or delivery systems
• Manufacturing processes
• Formulation stability

The Orange Book is the controlling source for patents listed against the FDA-approved product. Patent review should distinguish between patents listed for NDA 208254 and broader patents that describe topical corticosteroid formulations but do not necessarily cover IMPOYZ.

A practical patent-strength assessment should apply four tests:

Test	Strategic question
Claim coverage	Does the claim require the IMPOYZ concentration and excipient system?
Design-around exposure	Can a generic avoid infringement by changing one excipient or its concentration?
Validity	Are the formulation claims vulnerable to obviousness or enablement attacks?
Regulatory relevance	Would a non-infringing product still require a Paragraph IV certification?

Formulation patents are strongest when they require a narrow combination of measurable parameters that competitors cannot easily avoid without losing product performance. Broad claims covering a generic cream base are more vulnerable to prior-art and obviousness challenges.

Which companies are challenging IMPOYZ?

IMPOYZ faces competitive pressure from manufacturers of generic clobetasol propionate products rather than biosimilar developers. Because clobetasol propionate is a small molecule, the relevant FDA pathway is an abbreviated new drug application, not a biosimilar application under the Public Health Service Act.

Publicly available information does not establish a current, confirmed Paragraph IV litigation campaign specifically directed at IMPOYZ. A Paragraph IV challenge would require an ANDA applicant to certify that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The absence of publicly identified litigation does not remove generic-entry risk, particularly after regulatory exclusivity has expired.

What is the Paragraph IV risk?

The main Paragraph IV risks are:

• A generic cream matching the 0.025% strength
• A formulation that avoids a narrow excipient limitation
• A product relying on a different vehicle but seeking the same therapeutic equivalence category
• A challenge to formulation patent validity
• A launch after a litigation settlement or after patent expiry

For a branded topical product, the practical exposure is often greater from ordinary generic substitution and payer pressure than from a highly visible patent trial.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers for IMPOYZ are moderate rather than extreme. The product does not require biologic fermentation, aseptic filling, or a complex device. The technical barriers are concentrated in emulsion consistency and semisolid process control.

Important controls include:

• Clobetasol assay and uniformity
• Particle-size distribution
• Homogeneous drug dispersion
• Emulsion droplet-size control
• pH
• Viscosity and yield stress
• Microbial limits
• Preservative effectiveness
• Tube or pump compatibility
• In-use stability
• Scale-up mixing and cooling profiles

Process know-how can create a useful trade-secret position even when patent protection is weak. Critical process parameters may include order of addition, shear rate, temperature profile, neutralization sequence, cooling rate, and active-ingredient incorporation method.

What licensing and commercial opportunities exist?

The most realistic licensing opportunities are formulation and channel-based rather than asset-based.

Potential licensing structures

Opportunity	Commercial logic
Regional rights	Local partner handles registration, pricing, and distribution
Authorized generic	Brand owner monetizes product without abandoning the category
Co-branded dermatology portfolio	IMPOYZ becomes part of a broader psoriasis franchise
Device partnership	Pump or applicator company supplies differentiated packaging
Formulation out-license	Partner develops foam, gel, lotion, or preservative-free version
Payer contract	Rebates or preferred formulary placement defend volume
Specialty pharmacy channel	Supports adherence and patient services

A reformulated product may qualify for a new 505(b)(2) application if it contains a meaningful change in dosage form, formulation, route, or labeling and can rely partly on existing FDA findings. It would still require appropriate bridging evidence and may receive a separate three-year exclusivity period if approval is based on new clinical investigations essential to approval.

Revenue exposure

Public financial information does not identify standalone IMPOYZ revenue with sufficient reliability for a product-level forecast. The commercial exposure is best assessed through:

• Prescription volume
• Net price after rebates
• Share of prescriptions filled as cream rather than ointment or foam
• Payer coverage
• Generic substitution rates
• Specialty dermatology distribution
• Patient abandonment and refill persistence

The addressable market is established but price-sensitive. A premium strategy requires a demonstrable vehicle benefit. Without that benefit, generic clobetasol products will usually have the stronger payer position.

How strong is the IMPOYZ patent estate?

The patent estate should be considered moderate to weak for long-term exclusivity unless enforceable formulation or method-of-use claims remain active. The active ingredient is generic, the indication is established, and multiple topical clobetasol dosage forms are available.

Its strongest defensible assets are likely to be:

• Product-specific formulation claims
• Manufacturing know-how
• Trademark recognition
• Physician familiarity with the 0.025% concentration
• Distribution and payer contracts
• Patient-support infrastructure

Its weakest assets are:

• Broad claims to clobetasol treatment
• Generic cream composition claims
• Claims that do not require distinctive excipient ratios
• Commercial differentiation based only on brand identity

What generic launch scenarios exist for IMPOYZ?

Three launch scenarios are commercially plausible.

Scenario 1: Direct generic substitution

A manufacturer launches a 0.025% clobetasol propionate cream with an equivalent dosage form. This creates the greatest risk to IMPOYZ because the competing product can be substituted through pharmacy and payer channels.

Scenario 2: Vehicle-based competition

A competitor launches a lotion, gel, foam, or pump cream. This product may not substitute directly at the pharmacy level but can compete for prescriber preference, especially for scalp or hair-bearing areas.

Scenario 3: Brand-defense reformulation

The IMPOYZ owner launches a preservative-free, pump-delivered, lower-residue, or otherwise differentiated formulation. This can shift competition from price to adherence and patient experience, but it requires investment in development, regulatory strategy, manufacturing, and market access.

Key Takeaways

• IMPOYZ is clobetasol propionate 0.025% cream approved for short-term plaque psoriasis treatment.
• Its commercial differentiation comes from concentration and vehicle design, not a novel active ingredient.
• The listed excipients support emulsion stability, skin feel, drug release, preservation, and viscosity control.
• The strongest reformulation opportunities are preservative-free cream, pump delivery, fast-absorbing cream, foam, gel, lotion, and barrier-supportive vehicles.
• FDA regulatory exclusivity from the 2016 approval would have expired in 2019 under the standard three-year framework.
• Generic and Paragraph IV risk is materially more relevant than biosimilar risk.
• Patent value depends on narrow, product-specific formulation or method claims and should be confirmed against the current Orange Book entry for NDA 208254.
• Manufacturing know-how may provide more durable protection than broad formulation patents.
• A premium commercial strategy requires evidence of improved tolerability, adherence, dosing consistency, or application convenience.

FAQs

Is IMPOYZ stronger than hydrocortisone?

Yes. Clobetasol propionate is a very-high-potency topical corticosteroid, while hydrocortisone is a low-potency corticosteroid. Potency does not make IMPOYZ appropriate for all body sites or longer treatment durations.

Can IMPOYZ be reformulated without changing the active ingredient?

Yes. A new cream, foam, gel, lotion, spray, or delivery system can retain clobetasol propionate while changing the vehicle. The regulatory pathway depends on the extent of the formulation, dosage-form, labeling, and clinical changes.

Does a preservative-free IMPOYZ formulation have automatic market exclusivity?

No. Preservative-free status alone does not create automatic exclusivity. Protection would depend on applicable patents, regulatory exclusivity, trade secrets, trademarks, and the extent of any required clinical investigations.

Is a generic clobetasol product automatically substitutable for IMPOYZ?

No. Substitution depends on dosage form, strength, FDA therapeutic-equivalence designation, state pharmacy law, payer rules, and the specific prescription.

Can IMPOYZ be used for scalp psoriasis?

The cream may be difficult to apply to hair-bearing areas. A foam, solution, shampoo, or spray formulation may offer better delivery and cosmetic acceptability for scalp use, subject to separate regulatory support.

References

1. DailyMed. (n.d.). IMPOYZ: Clobetasol propionate cream, 0.025% prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2016). IMPOYZ (clobetasol propionate) cream, 0.025%: Labeling and approval information. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards. Center for Drug Evaluation and Research. https://www.fda.gov/drugs

5. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, Orange Book. Center for Drug Evaluation and Research. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm